Abstract | Technological advances in the laboratory have led to substantial improvements in clinical decision making through the introduction of pretreatment prognostic risk stratification factors in acute myeloid leukaemia (AML). Unfortunately, similar progress has not been made in treatment response criteria, with the definition of 'complete remission' in AML largely unchanged for over half a century. Several clinical trials have demonstrated that high-sensitivity measurements of residual disease burden during or after treatment can be performed, that results are predictive for clinical outcome and can be used to improve outcomes by guiding additional therapeutic intervention to patients in clinical complete remission, but at increased relapse risk. We review these recent trials, the characteristics and challenges of the modalities currently used to detect minimal residual disease (MRD), and outline opportunities to both refine detection and improve clinical use of MRD measurements. MRD measurement is already the standard of care in other myeloid malignancies, such as chronic myelogenous leukaemia and acute promyelocytic leukaemia (APL). It is our belief that response criteria for non-APL AML should be updated to include assessment for molecular complete remission and recommendations for post-consolidation surveillance should include regular monitoring for molecular relapse as standard of care.
Introduction
Our understanding of heterogeneity and the underlying disease biology of acute myeloid leukaemia (AML) has been greatly deepened by modern laboratory advances [1] [2] [3] [4] that have enabled more-refined pretreatment risk stratification using molecular prognostic 5, 6 and predictive 5 biomarkers. Unfortunately, this molecular revolution has been incompletely translated to the clinic. Just as the most-commonly used induction chemotherapy treatment for adult AML, excluding acute promyelocytic leukaemia (APL), has not changed substantially in the past 40 years, 7,8 the treatment response criteria for a 'complete remission' (CR) has not dramatically changed in almost 60 years 9,10 (Table 1) . It has been recognized since 1969 that a clinical 'complete remission' (CR) is an early, important and necessary, but insufficient step on the path to long-term disease control in AML. 11 Although a patient at first presentation with high blast count AML can have up to 10 12 leukaemic cells (equivalent to several pounds of solid tumour), that same patient after induction chemotherapy treatment judged to be in an initial CR might have as few as no leukaemic cells or as many as 10 10 leukaemic cells remaining (a number of cells equivalent to a 2 cm 3 solid tumour). 11 It is clear that owing to the low sensitivity criteria used, some CRs are more complete than others (Figure 1 ). Clinical decisions regarding subsequent treatment for patients in this highly diverse state of CR (to establish if the risks associated with stem-cell transplantation [SCT] as consolidation therapy are outweighed by a potential benefit from reduction in relapse risk 12 ) are currently made by stratification solely on the basis of pretreatment risk factors 5, 6 rather than any direct quantification of remaining leukaemic disease burden.
Many patients diagnosed with AML are not eligible for intensive chemotherapy, due to age or comorbidity. 13 However, in those who can tolerate such treatment initial CR rates of greater than 65% in newly diagnosed poorrisk leukaemias 14, 15 and up to 92-99% 16, 17 in those with core binding factor (CBF) AML are now achievable with optimal induction therapy, which has shifted the focus to the prediction and prevention of relapse.
In the current standard of care, pretreatment risk factor stratification assigns patients in an initial CR to a risk of relapse based on the average clinical outcomes of large historical populations who had similar pretreatment cytogenetic and molecular characteristics in their leukaemia at presentation. 6 ,10 This does not include any patient-personalized assessment of induction treatment efficacy by high-sensitive detection of residual leukaemia burden at the time that decisions regarding m ost-appropriat e consolidative treatment must be made.
The ability to measure minimal residual disease (MRD) in AML was not available in 1956 when criteria for the evaluation of response to treatment in acute leukaemia were proposed. 9 Therefore, understandably, thresholds were set based on the techno logy available at that time (Table 1) . MRD has, however, been measurable in patients with AML in a clinical CR via polymerase chain reaction 18 or flow cytometry 19 for over 20 years. Technologies used to detect MRD in acute leukaemia have included traditional expert microscopy for morphology, fluorescence in situ hybridization (FISH), cytogenetics, flow cyto metry, real-time quantitative PCR (RQ-PCR) for detection of overexpressed, rearranged or mutant sequences, DNA sequencing and, in the setting of monitoring post-SCT, analysis of chimerism by PCR or FISH (Figure 1 and Box 1). [20] [21] [22] [23] [24] There is already excellent evidence for clinical decision making as a standard of care based on multi-parameter flow cytometry in acute lymphoblastic leukaemia (ALL) 25 and RQ-PCR analysis in APL; [26] [27] [28] therefore, the remainder of this Review will focus solely on the use and opportunities of MRD in non-APL AML.
In this article we compare the modalities of MRD detection currently in use in AML by discussing recently reported clinical trials or series (Table 2) in terms of what they teach us regarding the optimal technology, indication, timing and predictive and prognostic utility of MRD measurements. We conclude by discussing clinical scenarios where we believe MRD measurement in AML could have immediate utility.
Gene overexpression in MRD detection
The development of RQ-PCR technology has provided many logistical and technological advantages compared to other MRD detection methodologies (Box 1). 20, 29, 30 The adaptation of this highly sensitive and specific technology to the quantification of disease burden in chronic myeloid leukaemia (CML) 31, 32 was responsible for fundamental contributions to drug development, 33, 34 response criteria and treatment guidelines, 35, 36 and detection and analysis of treatment failures 37, 38 in that disease. Unfortunately, no single rearranged or mutated target sequence analogous to the BCR-ABL fusion transcript in CML is found in all cases of AML, motivating the search for genes expressed at higher levels in AML than normal tissues that could serve as a target for RQ-PCR. Although a variety of such genes (for example, leukaemia associated antigens 39 ) are known and could potentially be used for this purpose, much of the work has focused on WT1. [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] WT1 is a zinc finger transcription factor with an essential role in normal development, with expression in the adult restricted to the renal glomerular podocytes and a subset of haematopoietic precursors. 53 It is overexpressed at the mRNA level in 80-90% of AML cases at diagnosis in both peripheral blood and bone marrow aspirate, and is detectable in a consistent low range in normal donors 40, 44, 47, 48 leading to its adoption in a standardized method for MRD detection using RQ-PCR. 48 A European LeukemiaNet study found the magnitude of WT1 log reduction after induction chemotherapy to be an independent predictor of relapse (<2 log reduction was associated with a 75% risk of relapse at 5 years compared to only 40% risk in those with a ≥2 log reduction). 48 Unfortunately, only 46% of 238 patient peripheral blood pretreatment samples examined had WT1 sufficiently overexpressed to allow the detection of a reduction of that magnitude. Peripheral blood seemed to be preferable to bone marrow aspirate for subsequent monitoring as higher levels of WT1 mRNA expression in healthy donor bone marrow (median 19.8 WT1 copies for every 10 4 copies of the housekeeping gene ABL, range: 0-213) compared to healthy donor peripheral blood (median 0.01 WT1 copies/10 4 ABL, range: 0.01-47.6) limited the working dynamic range for detection. Patients with WT1 levels above the upper limit of normal (250 copies/10 4 ABL in bone marrow aspirate or 50 copies/10 4 ABL in peripheral blood) after consolidation therapy were found to be at a significantly increased risk of relapse (67% versus 42% at 5 years). 48 Within the past year there have been some direct head-to-head comparisons of WT1 RQ-PCR assessment with other MRD modalities. Kwon et al. 52 described 21 patients with AML who were followed after allo geneic SCT using MRD monitoring with WT1 RQ-PCR geneexpression analysis, chimerism and flow cytometry. RQ-PCR was analysed using ddCt method 54 with GUS as a reference gene and using the cell line K562 as the calibrator sample, with >0.025% (peripheral blood) and >0.55% (bone marrow aspirate) considered to be positive results after two consecutive measurements. Four-colour Key points ■ Complete remission as currently defined in patients with acute myeloid leukaemia (AML) represents a highly heterogeneous state with a wide range of tumour burden and diverse clinical outcomes ■ Multiple high sensitivity methods exist for detecting AML minimal residual disease in patients in a morphological complete remission ■ Use of minimal residual disease status as a response criterion allows for the high sensitivity assessment of the efficacy of AML therapy ■ Minimal residual disease measurement during or after therapy for AML is prognostic and can risk-stratify patients to identify those most likely to benefit from escalated or additional therapy ■ For patients in complete remission minimal disease quantification of remaining leukaemic burden may supersede descriptors of disease biology (such as cytogenetics and molecular markers) for predicting subsequent risk of relapse ■ Thresholds can be established during post-treatment surveillance that when exceeded are predictive of future haematological relapse; therapeutic intervention at this stage can be effective in delaying or preventing relapse flow cytometry was performed, using at least 10 6 bone marrow cells, with a leukaemic aberrant phenotype of >0.1% considered positive. All of the nine relapses that occurred in these patients (range 50-560 days after SCT) were detectable using WT1 monitoring; in eight patients this 'molecular relapse' 23 preceded the clinical (that is haematological) relapse by a median of 137 days (range 52-462). Three of these relapsing patients had continuously elevated WT1 levels (that is, molecularly refractory) and six were initially negative for WT1 after SCT followed by a molecular relapse and haematological relapse. Eight of these nine patients had molecular relapse detectable from peripheral blood sampling, including all three patients with extra-medullary relapse. In no case was relapse detected by flow cytometry or mixed chimerism before WT1 positivity (although it should be noted that fewer time points were examined using these methodologies limiting the opportunities for early detection of relapse). A tenth patient also had elevated WT1 levels after SCT, but had not relapsed by the time of publication. All 11 patients without WT1 overexpression after SCT remained relapse free.
Miyazaki et al. 55 recently compared the use of flow cytometry with quantitative PCR for WT1 and/or leukaemia-specific fusion transcripts in 41 patients with acute leukaemia who had undergone allo-SCT. In their analysis of 156 samples, they demonstrated good concordance (71.8%) between flow cytometry and WT1 PCRbased MRD detection, with most of the discordance from samples that were PCR positive for WT1, but negative by flow cytometry. Unfortunately, this report included a mixture of patients with AML (n = 31) and ALL (n = 10) making additional interpretation challenging.
Rossi et al. 51 reported in 2012 on the use of six-colour flow cytometry with >0.1% leukaemia-associated immuno phenotypes (LAIPs) in bone marrow considered to be positive MRD compared to WT1 gene-expression profiling using RQ-PCR. In this single hospital series, of 47 consecutive patients with AML who had achieved a CR after induction chemotherapy, 23 were eligible for this study as they did not have leukaemia-specific re arranged or mutated genetic sequence suitable for MRD assessment. This study concluded that flow cyto metry and WT1 RQ-PCR "showed comparable capacity in terms of technical performance and clinical significance to identify high-risk patients who eventually relapsed", a surprising finding given that testing was not restricted to those ~50% of patients with WT1 mRNA elevated to a level where a 2-log variation could be detected. The mean expression of 3,320 copies WT1/10 4 ABL cell in the diagnosis samples used in this study would allow on average only slightly more than 1 log dynamic range, dramatically limiting the sensitivity. In addition, RQ-PCR testing was performed on bone marrow, and the threshold for positive MRD (90 copies/10 4 ABL) was within the reported range of expression observed in normal bone marrow samples and almost two thirds lower than the threshold determined in the prior standardization of this assay. 48 Given these factors, it is possible that this study compared flow cytometry with a conservative estimate of the optimal performance characteristics of the WT1 assay.
MRD in core binding factor AML
Similarly to APL AML, [26] [27] [28] the core binding factor (CBF) AMLs-defined as those carrying either the t(8,21) chromosomal translocation (RUNX1-RUNX1T1 fusion gene) or Inv(16)/t(16;16) rearrangement (CBFB-MYH11 fusion gene)-represent ideal AML subtypes for RQ-PCR-based MRD monitoring owing to the presence of a defined leukaemia-specific stable molecular target. The CBF AMLs represent up to approximately 20% of all AMLs in adults and are considered to be 'better-risk' or 'favourable risk' status based on cytogenetics and molecular stratifications.
5,6,10 Additional prognostic information in these subsets would be easily actionable; chemotherapy is often preferred for consolidation, so treatment escalation to SCT would be an option for those at the highest risk of relapse.
10, 12 Additionally, compared to other AML subtypes, effective salvage therapy is available for Inv(16) AML making post-treatment monitoring for early detection of relapse particularly important. 56 The AML02 trial 57 was a multicentre trial that treated 216 children for AML using risk-directed therapy based on leukaemia genetic factors at presentation and flow cytometry-based MRD, which achieved impressively high rates of CR (94% after second induction), 3-year event-free survival (EFS; 63%) and 3-year overall survival (71%). Flow cytometry-based MRD levels after induction therapy were important predictors of relapse, with flow Response criteria to assess efficacy of treatment are limited by the intrinsic detection limit of the test being used. Conventional clinical CR status represents a wide range of potential disease burden. Microscopic interpretation of morphology by an expert pathologist can detect, at best, a two log reduction in disease burden (1% limit of detection), while FC and PCR for overexpressed genes (GE-PCR, for example, WT1) have up to two log greater sensitivity (that is, ability to detect 1 abnormal cell in 10,000). PCR for fusion transcripts (such as core binding factor AMLs) and specific mutations (NPM1 mut ) by PCR (Mut-PCR) or NGS can detect residual disease with approximately 10,000-fold greater sensitivity than traditional CR criteria. Axis scales are approximate and solely for illustrative purposes. Abbreviation: AMLs, acute myeloid leukaemias; CR, complete remission; FC, flow cytometry; FISH, fluorescence in situ hybridization; MRD, minimal residual disease; NGS, next-generation sequencing.
cytometry MRD >1% after the first induction identified in multivariate analysis as being an independent adverse prognostic factor for both EFS and overall survival. 57 A study that was reported in 2012 58 retro spectively analy sed 508 samples from 77 of these patients who had a leukaemia-associated rearranged sequence (RUNX1-RUNX1T1, CBFB-MYH11 or MLL fusion transcripts) suitable for detection by PCR. There was good correlation between negative PCR results and flow cytometry; of 311 samples classified negative by PCR, 308 were also negative by flow cytometry. However, discrepancy was observed between positive PCR results and the flow cytometry results, with only 27 of 197 positive PCR results confirmed by flow cytometry. It is p ossible that this discrepancy is an artifact of the technology used to process earlier samples, because when modern RQ-PCR techno logy was used there was excellent correlation between PCR and flow cytometry results in 138 of 139 samples tested. 58 Another study was also reported in 2012, the MRC AML-15 trial was a prospective assessment of MRD using RQ-PCR to detect RUNX1-RUNX1T1 or CBFB-MYH11 transcripts in 278 patients aged 15-70 years who were being treated for CBF AML. 16 MRD was informative in the detection of molecular relapse preceding haematological relapse in serial monitoring during remission. Furthermore, the result of a single MRD assessment after completion of induction therapy while in CR was itself prognostic for subsequent relapse risk in a multivariate analysis that included age, white blood cell count (WBC), secondary AML, performance status and sex. After completion of induction chemotherapy to CR those 46% of patients with t(8,21) who had achieved a 3 log reduction in bone marrow MRD had a cumulative incidence of relapse (CIR) of only 4% (one relapse in 28 patients) compared to a CIR of 32% in the patients who did not achieve this level of initial leukaemic tumour burden reduction. Absolute levels of MRD were also significant with a threshold of <100 copies in bone marrow aspirate (47% of patients) identifying a cohort with a CIR of just 7% and the threshold of 1,000 copies in peripheral blood discriminated patients after induction into low (78% of patients, CIR 15%) and high (22% of patients, CIR 50%) risk groups. MRD assessment while in CR after induction therapy for inv(16) AML also allowed patients to be stratified-based on copy number in the peripheral blood-into low (<10 copies, 51% of patients, CIR 21%), intermediate (10-500 copies, CIR of 56%) and high (CIR of 100% for those with >500 copies) risk groups for subsequent relapse. Subsequent serial monitoring during remission after completion of all therapy for t(8,21) detection of >100 copies of RUNX1-RUNX1T1 transcript in the peripheral blood or >500 copies in bone marrow aspirate (that is, molecular relapse) was associated with a haematological relapse rate of 100% compared to only 7% in those below this threshold. Similar thresholds could be established to be significantly prognostic of relapse risk for Inv (16) patients in CR after completion of therapy by MRD monitoring of the Inv(16) transcript in bone marrow aspirate (>50 copies, 32% of patients, 100% haematological relapse rate compared to a CIR of 10% in those with ≤50 copies and peripheral blood; >10 copies, 28% patients, 97% haematological relapse risk compared to a CIR of 7% in those with ≤10 copies).
Finally, results from the CBF-2006 trial were reported in early 2013. 17 This trial assessed the treatment of 198 adults aged 18-60 years with newly diagnosed CBF AML using prospective evaluation of pretreatment leukaemia molecular factors (FLT3, KIT and RAS mutations) with MRD assessment for relapse risk-stratification. 17 MRD levels were determined from bone marrow aspirate using RQ-PCR before three monthly consolidation cycles of cytarabine (3,000 mg/m 2 over 12 h) on days 1, 3 and 5 followed by GCSF from day 8 to neutrophil recovery. Patients were randomly assigned to one of two induction regimens resulting in similar initial post-induction conventional (haematological) CR rates of 98-100%. However, MRD assessment could distinguish between the efficacy of these induction regimens, demonstrating differences in the depth of remission and the residual disease burden after induction (0.10% versus 0.26% fusion transcript ratios), a difference that seemed to persist after subsequent consolidation cycles. Univariate analysis of post-CR prognostic risk factors identified high WBC, KIT mutations, FLT3 mutations, less than a 3-log reduction in MRD after first cycle of consolidation (MRD2) and an absolute MRD2 level of >0.1% as factors associated with subsequent relapse. Multivariate analysis of WBC, KIT and FLT3 mutations, and MRD2 response showed that MRD2 response (by 3-log reduction or absolute level) was the sole factor influencing specific hazard of relapse both in the whole patient cohort, and also in the individual t(8,21) and Inv (16) subsets. This suggestion that when prognosticating relapse risk the reality of disease burden after treatment (MRD) might trump 59 and seem to be a stable marker for MRD monitoring. 60, 61 The German-Austrian AML study group reported on the prospective use of NPM1 mut MRD in 245 adults (age 19-61 years) with AML. 59 The degree of disease burden as measured by NPM1 mut RQ-PCR MRD was significantly associated with prognosis for patients in CR when measured after each cycle of treatment. For example, MRD negativity after completion of induction therapy was associated with a 4-year CIR of only 6.5% (achieved by 26 patients) compared to a CIR rate of 53% in the 111 patients in morphological CR, but not achieving this molecular CR milestone (P <0.001). Additionally, 4-year CIR was 15.7% (overall survival 80%) in the 62 CR patients who were MRD negative at the completion of therapy compared to a CIR of 66.5%, P <0.001 (overall survival 44%, P <0.001) in those in CR, but who were MRD positive. Although bone marrow aspirate MRD assessment was preferable for high sensitivity detection of MRD during therapy, peripheral blood MRD showed good concordance (88%) with bone marrow in posttreatment monitoring. When a threshold of 200 copies NPM1 mut /10 4 ABL was exceeded it was 100% predictive of relapse. 59 Of note, only 9% of evaluable relapses had no or minimally detectable NPM1 mut at the time of relapse, confirming the relative stability of this target. Similar results were shown by Miglino et al., 62 where achievement of a NPM1 mut molecular CR after induction was associated with a statistically significantly lower risk of relapse than for those patients who remained with detectable disease, and a statistically significantly higher overall survival at 36 months (64.3% versus 11.9% for MRD-negative versus MRD-positive disease, P <0.03).
62

NPM1
mut molecular relapse was invariably associated with eventual h aematological relapse. 62 Further to these results, Shayegi and colleagues recently demonstrated, in a retrospective study of 174 patients, that a specific NPM1 mut MRD threshold level (>1% NPM1 mut /ABL1) can be determined in patients in CR after chemotherapy, and in a multi variate analysis 63 Interestingly, using ultra-deep next-generation sequencing they were able to show using mutant to wild type allelic ratios that this level of MRD was equivalent to approximately 1 in 30,000 cells (that is, in the same range as the 10 -4 detection limit currently possible using flow cyto metry). Finally, analysis of 138 paired blood and bone marrow samples from this study showed greater than 82% concordance in the detection of MRD. While the specific threshold limits in this study were established for bone marrow specimens and bone marrow examination is likely still preferable because of high sensitivity at key clinical time points (such as after completion of induction and consolidation therapy), this work suggests frequent s ampling from peripheral blood during the post-treatment surveillance phase could reason ably take the place of bone marrow testing for this particular MRD assay with obvious patient comfort, cost and logistical advantages. 63 Despite evidence that the approximately 50% of AMLs with sufficient WT1 overexpression for MRD monitoring includes many cases of NPM1 mut , Inv(16) or adverse cytogenetic AML, 48 it is nevertheless likely that a validated and stable molecular target for RQ-PCR MRD monitoring can be found for the majority (perhaps 65-75%) of patients diagnosed with AML. Additional stable molecular markers with potential for development for MRD monitoring include DNMT3A 64 and CEBPA. 65 Despite initial concerns that tracking the FLT3-ITD mutation (seen in approximately 30% of cases of AML 5 ) would not be informative, owing to concerns regarding stability between diagnosis and relapse, 66 recent studies have confirmed that tracking this mutation is useful for the early detection of relapse. [67] [68] [69] It is likely that clinical laboratories will have to offer a portfolio of RQ-PCR MRD assays, which will probably increase as assessment of AML samples using nextgeneration sequencing technology increases the number of viable molecular targets.
3 Once whole-genome and/or whole-exome sequencing of tumour and germline samples becomes routinely possible for cancer diagnosis, 70 this data will facilitate identification of not only patient-specific MRD markers, 71 but also allow molecular diagnosis, 72 subsequent retrospective discovery of prognostic factors, 5 and triage to the most appropriate trials of targeted agents. 73 Finally, the ability to identify stable molecular targets within the leukaemic stem-cell population [74] [75] [76] for MRD monitoring and therapeutic t argeting is of obvious great interest.
Flow cytometry for MRD in AML
Flow cytometry is, when used by appropriate experts, an excellent method for determining MRD in AML with high sensitivity and specificity. 22, 57, [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] Some of the advantages and logistical challenges associated with this method are outlined in Box 1. Modern flow-cytometry-based MRD detection is mostcommonl y based on the definition of aberrant cell surface marker expression in AML cells as a leukaemia associated phenotype (LAP or leukaemia-associated immunophenotype, LAIP) that is not, or only infrequently, seen in normal or recovering bone marrow or blood. 80, 88 These markers can include asynchronous expression of early and late antigens, cross lineage infidelity (for example, expression of lymphoid markers on myeloid cells) and antigen underexpression or overexpression. 80, 82 Such LAIPs can be personalized to each patient at presentation, with the caveat that AML is a clonal disease and relapsed disease might have a d ifferent immunophenotype. 81, [89] [90] [91] [92] The main advantage of flow cytometry over PCRbased methods in MRD monitoring is its near-universal applicability; 94% of patients had a suitable LAIP for use in one study, 93 with a range reported in the literature (when at least three-colour flow cytometry is used) of 60-100%. 80 We avoid in this Review the ungainly terminology of 'immunological relapse' and 'immunological complete remission' when describing the reappearance or absence of MRD as detected by flow cytometry; however, the levels of MRD necessary for the molecular response criteria described by Hokland and Ommen 23 can also be detected by modern flow cytometry. It is unclear if quantitative MRD results can be compared across multiple centres given the importance of human and technical factors 24 in interpretation; indeed, even in the context of a clinical trial with identical standard operating procedures, reagents and instruments used, variation was seen between four reference laboratories. 82 Given the extremely successful experience of using flow cytometry for the detection of MRD in patients with ALL 25 paediatric oncologists have been leaders in using this technology in AML. An example of this leadership is in the design and implementation of the AML02 study already discussed, 57 where subsequent analysis determined that flow cytometry-based MRD measurement after first and second induction was significantly a ssociated with 5-year EFS and overall survival. 58 A cohort of 219 patients with AML under the age of 21 years treated on the AAML03P1 trial 94 was recently analysed for MRD using four-colour flow cyto metry using a non-LAIP based 'difference from normal' approach. 95 In 188 patients with initial morphological CR after the first induction phase, the presence of flow cytometry-defined MRD (seen in 25% of patients) correlated well with relapse (3-year relapse risk 60% versus 29% in MRD-negative patients). Cytogenetic and molecular risk factors were associated with risk of MRD while in CR after first induction; 11%, 29% and 50% of those patients with favourable-risk, intermediate-risk and high-risk cytogenetics were positive for MRD at this time point, respectively, and 25% of those with FLT3-ITD were MRD positive compared to 0% of those with NPM1 mutations. A multivariate analysis that included molecular-risk-group stratification and WBC at presentation as variables demonstrated that MRD positivity after first induction was an independent predictor of poor relapse-free survival (RFS) for those patients in morpho logical CR. 94 Interestingly, of the 27 patients who did not achieve a morphological CR (>5% blasts) after first induction therapy, seven were found to be negative for residual disease by flow cytometry and clinically remain long-term survivors. Finally, highlighting the increased logistical and resource implications of providing high-quality flow cytometry-based MRD assessment, this study required all analyses to be performed by two independent analysts with concordance necessary for MRD diagnosis. 94 Flow cytometry for MRD in adults with AML can also be prognostic. A retrospective analysis of 123 adults enrolled in EORTC/GIMEMA protocols in the period 1998-2008 in a single centre, showed that flow cytometry-based MRD at the end of consolidation could blur distinctions between pretreatment cytogenetic and molecular-risk groups. 96 For example, after consolidation patients in CR with good-risk karyotype AML, but who were MRD positive, had a 4-year RFS of only 15% compared to those in CR who were MRD negative and who had intermediate-risk karyotype AML who had a 4-year RFS of 63%. The use of post-consolidation flow cytometry-based MRD status combined with pretreatment cytogenetics and FLT3 mutational status could segregate patients into groups with low or high risk for subsequent relapse. Further analysis focused on the effect of autologous SCT (auto-SCT) or allogeneic SCT (allo-SCT) in the 79 patients who received one of these therapies as post-consolidation therapy. There was no statistical difference in outcome in low-risk patients (but there were five non-relapse transplant-related deaths in the allo-SCT group), but superior outcomes were seen after allo-SCT for patients in the high-risk category (RFS of 47% for allo-SCT versus 13% for auto-SCT). These data suggest that MRD-directed therapy escalation can improve outcomes. 96 Within any individual patient, AML is not a single homogenous disease at the level of genetics and disease biology.
1,3,4 Using flow cytometry, Gerber et al. 75 identified a population of cells that although rare in leukaemia at diagnosis seemed to be significantly overrepresented in the MRD fraction in patients in a morphological CR after treatment. These cells were capable of producing complete leukaemic engraftment in an immunodeficient mouse model of stem cell function. The presence of such cells in patients after treatment was highly correlated with subsequent clinical relapse; of 11 patients who achieved morphological CR after induction therapy all four with this "leukaemic stem cell" (LSC) pattern relapsed while all seven patients without this LSC MRD remain relapse free at an average follow-up of 509 days (P = 0.003). This important finding is now the basis of an ongoing clinical trial at Johns Hopkins Hospital to determine the 2-year RFS of patients with AML who have detectable 'LSC' at first CR who receive either chemotherapy or SCT (NCT01588951). The tracking of LSC MRD represents another unique advantage of flow cytometry until such a time when unique molecular markers of such cancer stem cells can be identified; this is an area of much interest.
3,74-76,97-104 MRD in the setting of allo-SCT Allo-SCT remains the first and most effective immunotherapy used to treat haematological malignancies. 39 Therefore, the possibility of using MRD to enable appropriate triage of patients pretransplantation based on their individual risk of relapse and to follow patients and treat before frank clinical or haematological relapse is of obvious interest. 96, [105] [106] [107] [108] [109] In addition to those studies already discussed, there are several other studies that directly address the role of MRD testing in the peritransplant setting. For example, Walter et al. 79 used a 'difference from normal' flow cytometry-based MRD approach in patients in conventional CR before allo-SCT to show that 2-year relapse rate (64.9% versus 17.6%) and overall survival (30.2% versus 76.6%) were markedly different in the group positive and negative for MRD, respectively. This increased mortality risk in patients who were MRD positive before allo-SCT remained statistically significant even when adjusting for other factors. 79 This worse outcome in patients who are in conventional CR, but are MRD positive before allo-SCT has also been seen when using cytogenetic 110 and WT1 PCR MRD testing. 50, 106, 111 For example, Pozzi et al. 106 reported on the use of WT1 PCR to predict relapse risk in 122 patients with AML who received allo-SCT. Using a threshold of 100 WT1 copies/10 4 copies of ABL, MRD testing using WT1 levels was highly predictive of relapse risk in the pretransplant setting (69 MRD-negative patients had a relapse rate of 26% versus a relapse rate 53% in the 53 patients who were MRD positive) and post-transplant setting (only 16% of 55 MRD-negative patients relapsed, compared to 55% of 67 MRD-positive patients). Combining information from pre transplant and post-transplant time points seemed to be especially informative.
Can MRD guide therapy?
Beyond providing patients with prognostic information, detection of MRD is only useful if therapeutic intervention is available that can change the course of the disease (Figure 2) . Evidence for effective MRD-based risk-directed therapy has already been discussed; in AML02, 57 levels of MRD during induction were used to determine the timing and need for escalation of induction therapy, and then a combination of initial risk classifi cation and MRD-based assessment of induction response was used to assign appropriate consolidation therapy. This MRD-directed approach resulted in superi or outcomes compared to earlier trials with 3-year EFS (63%) and overall survival (71%).
Multiple reports of treatment of molecular relapse before clinical or haematological relapse have shown that MRD-directed therapy can lead to improved clinical outcomes. CD34
+ donor chimerism analysis is a specific method for monitoring for MRD after allo-SCT, 112 with a chimerism level falling below 80% after SCT a har binger of haematological relapse in a median of 61 days. 113 Data from the RELAZA trial 114 demonstrated treatment with four cycles of azacitidine in patients with AML who had MRD with CD34 + chimerism falling below 80% could delay haematological relapse to a median of 231 days and led to continuous RFS in 20% of patients without any further treatment. Analogously, it has been shown that rising NPM1 mut MRD levels are predictive of upcoming haematological relapse in a median time of 8 weeks. 61 Sockel et al. 115 treated 10 patients with AML in CR, but who had increasing NPM1 mut MRD levels with azacitidine therapy with a resulting molecular response (at least 1 log reduction in MRD levels) in seven of these patients, with seven remaining in a complete h aematological response after a median follow-up of 10 months. 115 In the Pozzi study already discussed, 106 retrospective analysis suggested that patients with rising WT1 MRD who received immunotherapy in the form of donor lymphocyte infusions (DLI) had a better 5-year overall survival (44%) than those with rising WT1 MRD levels who did not receive DLI. However, this nonrandomized study has several confounding factors that make interpretation challenging, which was exacerbated by the fact that time to haematological relapse was not different between the two groups. There is strong evidence that DLI can be an efficacious intervention in the setting of MRD relapse. Yan et al. 116 analysed data from 814 patients aged 2-59 years who received SCT (for AML, ALL or myelodysplastic syndrome (MDS)-refractory anaemia with excess blasts) from a single centre in the period 2006-2010. The 105 patients who were determined to be MRD positive by flow cytometry or WT1 RQ-PCR after SCT were treated with either interleukin-2 (IL-2) and/or modified DLI. Presence of MRD after SCT was associated with greater 3-year CIR than those patients without MRD (46% versus 18.1%). Significant differences at 3 years were seen within the MRD-positive group based on the modality used to treat their molecular relapse; CIR of 64.4% (overall survival of 28.1%) in those treated with IL-2 alone compared to CIR of only 27.8% (overall survival of 58.3%) in those treated with DLI. In fact, CIR and disease-free survival was not statistic ally different between the MRDnegative patients and those MRD-positive patients who were treated with DLI. Unfortunately, responses for patients with AML who had MDS were not reported separately from those in patients with ALL.
A further study assessed MRD-directed therapy for patients with t(8,21) AML. 117 MRD determined by RUNX1-RUNX1T1 transcript levels by RQ-PCR was shown to be predictive for relapse when measured after the second cycle of consolidation. A nonrandomized comparison of those in a high-relapse-risk group (defined by being in a morphological CR, but who were positive for MRD after second consolidation) who received allo-SCT as mandated by risk-directed protocol (n = 40) compared with those who did not owing to patient preference or lack of appropriate donor (n = 29) showed a substantial benefit to this escalation of therapy (CIR 22.1% versus 78.9%, P <0.0001). However, in patients in the low-risk group (CR and MRD negative after second consolidation), a benefit from allo-SCT was not seen. These observations need confirmation in a random ized trial, but add to the increasing body of evidence that not only is MRD prognostic, but that therapy based on MRD might improve clinical outcomes.
Conclusions
Despite the challenges in standardizing definitions of assay-specific and AML-specific thresholds of MRD and the lack of one universal modality or target, there is now evidence that MRD monitoring can improve relapse risk stratification and detection in AML. The use of MRD to guide treatment is already an accepted standard of care in ALL, 25 CML 35 and APL, 26, 28 and based on recent studies discussed here 16, 17 will also soon be standard of care in patients with CBF AML. 118 In the CBF AML MRD trials, the average kinetics of relapse seemed to be approximately 0.5-0.6 log per month, MRD was checked every 3-4 months in peripheral blood in the first 2-year period when most relapses occurred and the median lead time between molecular relapse and haematological relapse was 3-4.5 months. 16 Although disease biology might influence the kinetics of relapse, 23 detection modality used will influence the lead time between molecular and haematological relapse, 24 it now seems clear that regular MRD monitoring could be easily integrated into the current recommendations for postconsolidation surveillance of a peripheral blood draw for complete blood count with platelets every 1-3 months for the first 2 years.
10 Detection of MRD in a previously MRD negative patient, using either RQ-PCR or flow cyto metry, could provide a therapeutic window for i ntervention before frank clinical relapse.
The search for optimal MRD assessment in other AML types will be an iterative process and the understandable quest for the perfect should not become the enemy of the introduction of the better; even low-sensitivity MRD to a modest 10 -4 detection threshold (Figure 1 ) might provide more-actionable information than traditional haematological CR. 120 There are a number of specific clinical scenarios where the adoption of routine standard of care MRD monitoring could make an i mmediate impact (Box 2).
MRD thresholds do not need to be infallibly associated with evitable haematological relapse to be clinically useful, the concept of maintenance therapy for prevention of relapse in those at increased risk is already under investigation in myeloma, 121 follicular lymphoma 122 and lung cancer. 123 As less-toxic therapies with efficacy in leukaemia become available, 39, [124] [125] [126] [127] identification of patients at the greatest risk of relapse who might benefit from such additional therapy in the post-conventional treatment setting would be particularly useful. Similarly, monitoring for the early detection of the development of subclinical disease would also have utility for those therapies, including immunotherapies, where optimal effects might be observed in lower disease burden states. 39, 74, 128, 129 Standardized molecular CR criteria will likely also aid drug development. Haematological CR is a blunt tool to evaluate differences between therapies, and MRD measure ment offers greater dynamic range to detect changes in leukaemia burden 17 and monitor for treatment effect on leukaemic subpopulations that might be associated with relapse.
4, 75 The ability to escalate or de-escalat e therapy based on MRD response might increase the number of patients with AML who can undertake therapy with curative intent. Currently, many patients who are diagnosed with AML do not receive best available therapy, 13 and these patients might benefit from the titration of safe, moderately effective therapy based on the objective high sensitivity response criteria of MRD.
How the results of MRD assessments are ultimately integrated into standard cytogenetic and molecular risk stratification systems remains an open question 130 that ultimately will be only answered by prospective clinical trials. Although there is clear evidence that disease biology in the form of pretreatment risk stratification factors influence risk of having residual disease after initial treatment, 94 it seems that deep negativity in MRD measurements post-treatment is an independent protective factor against relapse and that this factor may trump other considerations in some, 17, 63 but not all 96 situations. Many recent excellent reviews, editorials and comment pieces have advocated for the incorporation of MRD monitoring into AML clinical trials. 20, [22] [23] [24] 30, [131] [132] [133] [134] [135] It is our hope that by reviewing the most-recent clinical trial results in this area we might add our voices to this chorus. Although much work remains to standardize the timing, performance, indications and application of MRD monitor ing across multiple centres these challenges should not preclude, in the meantime, the more immediate establishment of local AML MRD monitoring capacity. Given our belief that the current standard of care therapy for patients in the USA diagnosed with AML, if treated with curative intent, is referral to a specialized centre where an appropriate clinical trial can be offered, 136 we would add now an additional characteristic that such a leukaemia centre of excellence would have the capacity to routinely provide MRD monitoring for the majority of cases of AML and to universally integrate such m onitoring into all future therapeutic clinical trials.
Box 2 | Scenarios in the care of patients with AML where MRD might have use ■ High-resolution determination of efficacy of therapy ■ To allow target-driven titration of dose and duration of treatment ■ Relapse risk stratification after induction to allow triage to optimal consolidation therapy ■ To determine prognosis after completion of standard treatment ■ To spare toxicity and cost of stem-cell therapy in those with low risk of relapse ■ Assignment to maintenance therapy after completion of standard treatment
